SE407333B - Forfarande for rening av gamma-globulin, serskilt antilymfocyt-gamma-globulin - Google Patents
Forfarande for rening av gamma-globulin, serskilt antilymfocyt-gamma-globulinInfo
- Publication number
- SE407333B SE407333B SE7209600A SE960072A SE407333B SE 407333 B SE407333 B SE 407333B SE 7209600 A SE7209600 A SE 7209600A SE 960072 A SE960072 A SE 960072A SE 407333 B SE407333 B SE 407333B
- Authority
- SE
- Sweden
- Prior art keywords
- globulin
- stroma
- erythrocyte
- solution
- acrinol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000000746 purification Methods 0.000 title claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 title description 41
- 210000003743 erythrocyte Anatomy 0.000 claims description 27
- 230000000890 antigenic effect Effects 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 21
- 108010017384 Blood Proteins Proteins 0.000 claims description 20
- 102000004506 Blood Proteins Human genes 0.000 claims description 20
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 19
- 230000009102 absorption Effects 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 238000005119 centrifugation Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 239000012503 blood component Substances 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims 4
- 108010044091 Globulins Proteins 0.000 claims 4
- 239000012153 distilled water Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000283073 Equus caballus Species 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- QWAGALBSTFENEE-UHFFFAOYSA-N 4-aminoacridine Chemical compound C1=CC=C2N=C3C(N)=CC=CC3=CC2=C1 QWAGALBSTFENEE-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000009261 D 400 Substances 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- -1 halogen salts Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052749 magnesium Chemical class 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/837—Lymph; lymph-glands; thymus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/838—Marrow; spleen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16569771A | 1971-07-23 | 1971-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE407333B true SE407333B (sv) | 1979-03-26 |
Family
ID=22600062
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7209600A SE407333B (sv) | 1971-07-23 | 1972-07-21 | Forfarande for rening av gamma-globulin, serskilt antilymfocyt-gamma-globulin |
| SE7809384A SE447339B (sv) | 1971-07-23 | 1978-09-06 | Forfarande for separation av erytrocytstroma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7809384A SE447339B (sv) | 1971-07-23 | 1978-09-06 | Forfarande for separation av erytrocytstroma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3745155A (en:Method) |
| JP (1) | JPS5732044B1 (en:Method) |
| AR (1) | AR192808A1 (en:Method) |
| AU (1) | AU461489B2 (en:Method) |
| BE (1) | BE786564A (en:Method) |
| CA (1) | CA971880A (en:Method) |
| CH (1) | CH584126A5 (en:Method) |
| DE (1) | DE2235600C3 (en:Method) |
| DK (1) | DK132689C (en:Method) |
| FR (1) | FR2147100B1 (en:Method) |
| GB (2) | GB1377101A (en:Method) |
| IL (1) | IL39911A (en:Method) |
| NL (1) | NL173918C (en:Method) |
| SE (2) | SE407333B (en:Method) |
| ZA (1) | ZA724738B (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2222084B1 (en:Method) * | 1973-03-22 | 1976-05-14 | Fontaine Michel | |
| NL7602422A (nl) * | 1976-03-08 | 1977-09-12 | Leuven Res & Dev Vzw | Trombosetest. |
| IT1143768B (it) * | 1977-10-31 | 1986-10-22 | Boehringer Biochemia Srl | Procedimento per la produzione di un anticorpo anti-hcg,particolarmente utile per la diagnosi della gravidanza |
| US4731336A (en) * | 1982-06-14 | 1988-03-15 | Amersham International Plc | Immunoassay for complement fragments |
| US5219578A (en) * | 1991-02-25 | 1993-06-15 | Innovet, Inc. | Composition and method for immunostimulation in mammals |
| GB201520903D0 (en) | 2015-11-26 | 2016-01-13 | Qbd Qs Ip Ltd | Purification method |
-
0
- BE BE786564D patent/BE786564A/xx not_active IP Right Cessation
-
1971
- 1971-07-23 US US00165697A patent/US3745155A/en not_active Expired - Lifetime
-
1972
- 1972-07-04 AR AR242887A patent/AR192808A1/es active
- 1972-07-10 CA CA146,736A patent/CA971880A/en not_active Expired
- 1972-07-11 GB GB3241672A patent/GB1377101A/en not_active Expired
- 1972-07-11 GB GB2429574A patent/GB1377102A/en not_active Expired
- 1972-07-11 ZA ZA724738A patent/ZA724738B/xx unknown
- 1972-07-13 CH CH1054272A patent/CH584126A5/xx not_active IP Right Cessation
- 1972-07-14 IL IL39911A patent/IL39911A/xx unknown
- 1972-07-14 AU AU44582/72A patent/AU461489B2/en not_active Expired
- 1972-07-19 NL NLAANVRAGE7209952,A patent/NL173918C/xx not_active IP Right Cessation
- 1972-07-20 DE DE2235600A patent/DE2235600C3/de not_active Expired
- 1972-07-21 DK DK363972A patent/DK132689C/da active
- 1972-07-21 SE SE7209600A patent/SE407333B/sv unknown
- 1972-07-21 FR FR7226377A patent/FR2147100B1/fr not_active Expired
- 1972-07-24 JP JP7351172A patent/JPS5732044B1/ja active Pending
-
1978
- 1978-09-06 SE SE7809384A patent/SE447339B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE447339B (sv) | 1986-11-10 |
| DE2235600A1 (de) | 1973-02-01 |
| SE7809384L (sv) | 1978-09-06 |
| CH584126A5 (en:Method) | 1977-01-31 |
| GB1377102A (en) | 1974-12-11 |
| NL7209952A (en:Method) | 1973-01-25 |
| CA971880A (en) | 1975-07-29 |
| IL39911A (en) | 1975-04-25 |
| JPS5732044B1 (en:Method) | 1982-07-08 |
| AR192808A1 (es) | 1973-03-14 |
| DE2235600B2 (de) | 1980-10-02 |
| NL173918C (nl) | 1984-04-02 |
| BE786564A (fr) | 1973-01-22 |
| GB1377101A (en) | 1974-12-11 |
| ZA724738B (en) | 1973-03-28 |
| IL39911A0 (en) | 1972-09-28 |
| DK132689B (da) | 1976-01-26 |
| FR2147100B1 (en:Method) | 1976-08-06 |
| AU4458272A (en) | 1974-01-17 |
| DE2235600C3 (de) | 1981-07-30 |
| AU461489B2 (en) | 1975-05-29 |
| FR2147100A1 (en:Method) | 1973-03-09 |
| US3745155A (en) | 1973-07-10 |
| DK132689C (da) | 1976-07-26 |
| NL173918B (nl) | 1983-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schrohenloher et al. | Activity of dissociated and reassociated 19S anti-γ-globulins | |
| Alter et al. | Further studies on a" new" human isoprecipitin system (Australia antigen) | |
| US4357272A (en) | Recovering purified antibodies from egg yolk | |
| Jorpes | The protein component of the erythrocyte membrane or stroma | |
| Frommhagen et al. | The role of aggregated γ-globulins in the anticomplementary activity of human and animal sera | |
| Stern et al. | Electrophoresis in medicine | |
| NO753638L (en:Method) | ||
| JP2009521520A (ja) | 抗Ａおよび抗Ｂ抗体、ならびに多反応性ＩｇＧが減少した免疫グロブリンＧ（ＩｇＧ）濃縮物 | |
| TWI226834B (en) | Process for selectively isolating antibody isomers | |
| Gerin et al. | Biophysical Characterization of the adr Subtype of Hepatitis B Antigen and Preparation of Anti-γ Sera in Rabbits | |
| JPH0354120B2 (en:Method) | ||
| Shedlovsky et al. | THE LS-ANTIGEN OF VACCINIA: II. Isolation of a Single Substance Containing Both L-and S-Activity | |
| US2793203A (en) | Process of preparing stable, highly purified gamma globulin preparations | |
| SE407333B (sv) | Forfarande for rening av gamma-globulin, serskilt antilymfocyt-gamma-globulin | |
| Lennette et al. | Studies on epidemic influenza virus: The nature and properties of the complement-fixing antigen | |
| US3903254A (en) | Separation of erythrocyte stroma from lysing medium and hemoglobin with acrinol | |
| Zanetti et al. | Passive Heymann's nephritis as a model of immune glomerulonephritis mediated by antibodies to immunoglobulins | |
| EP0068465B1 (en) | Non-a, non-b hepatitis-associated antibody conjugate, the use thereof and detection reagent | |
| US3607857A (en) | Process of removing acrinol from gamma globulin using siliceous material such as silica gel | |
| US20090181043A1 (en) | Method for Producing Human Anti-Thymocyte Immunoglobulins | |
| JPH0118080B2 (en:Method) | ||
| US4197238A (en) | Method of preparation of human albumin using polyethylene glycol | |
| JP2008534687A (ja) | タンパク性物質からタンパク質を単離するための高分離方法及び沈殿試薬 | |
| Spooner et al. | The isolation of ox red cell membrane antigens: antigens associated with sialoprotein | |
| US3203865A (en) | Hog serum antibody concentrate |